Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 133

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 133
---
40mg. Although MEAI remains in development and is not cleared or approved by the FDA or similar foreign regulatory bodies, we believe that our drug candidate has the potential to change the lives of millions who struggle to drink in moderation. We believe that MEAI holds the potential to break the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behavior”. Research Programs Our IP portfolio is composed of several neuroplastogen molecules and we successfully conducted research in several programs on different molecules, which were led by our highly skilled, focused team, with deep expertise in their respective fields. Several of our team members have taken products from the discovery phase to clinical trials in the United States in their previous respective roles and are also key members of our scientific advisory board who have participated in numerous clinical trials in the areas of alcoholism and addiction. We are currently focusing our research programs on the uses of MEAI for the treatment of AUD, obesity and metabolic disorders and as an alcohol substitute consumer product. 81 In our research program aimed at treating depression and treatment resistant depression, or TRD, we studied the effects of administering 2-fluorodeschloroketamine, or 2-FDCK and we investigated 2-FDCK in a pre-clinical proof-of-concept study. Following the completion of the study, while we do not have any immediate plans to further investigate this now, we may in the future further investigate the effect of depression and the mechanisms of action around it. In our two research programs aimed at finding substances that can be utilized for the same therapeutic purposes as MDMA, we studied 1-(Benzofuran-5-yl)-N-methylpropan-2-amine, or 5-MAPB and 1-Benzofuran-6-yl propan-2-amine, or 6-APB. We believe these treatments may be beneficial for fail-safes for MDMA based on a September 2016 article from Naunyn-Schmiedeberg’s Archives of Pharmacology, which reported the receptor binding profiles of 5-MAPB and 6-APB are different enough from MDMA to effectively perform a substitute role in the therapy while being similar enough so as not to have to change the therapeutic protocol. We currently hold patents with respect to the compounds, but we do not have any immediate research plans. Strategic Focus With respect to our AUD programs, we developed